Car T-Cell Therapy

A single infusion of ALLO-316 provided a high rate of disease control for patients with advanced or metastatic renal cell carcinoma, results from the phase 1 TRAVERSE trial showed.

Physicians recommended chimeric antigen receptor T-cell therapy more frequently than any other regimen for third-line treatment of relapsed or refractory diffuse large B-cell lymphoma, survey results showed.

Despite an overall positive safety outlook, the scope of potential toxicities related to chimeric antigen receptor T-cell therapy remains unclear due to lack of long-term follow-up.

Miguel-Angel Perales, MD, has been named president of American Society for Transplantation and Cellular Therapy for 2023-2024.

Carl H. June, MD, will receive this year’s AACR Award for Lifetime Achievement in Cancer Research.

Bellicum Pharmaceuticals discontinued clinical trials for two investigational chimeric antigen receptor T-cell therapies, the company announced today.

SCOTTSDALE, Ariz. — Several new drugs and promising therapies, including chimeric antigen receptor T-cell therapy, have ushered in a “lupus renaissance,” said a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

Researchers developed a highly accurate model that can predict which patients will achieve complete response to chimeric antigen receptor T-cell therapy for multiple myeloma.

Healio | HemOnc Today is excited to announce a new physician leadership structure, which features seven Associate Medical Editors from various subspecialty areas within oncology and hematology.

A novel chimeric antigen receptor T-cell therapy induced response among adults with advanced large B-cell lymphoma who relapsed after previous CAR-T, study results showed.